Dr David Tan is a consultant medical oncologist and clinician scientist at the National University Cancer Institute, Singapore. His primary clinical and research interests are in gynaecological (ovarian, endometrial and cervical) cancers and the development of novel anti-cancer therapeutic agents.
Dr Tan graduated with a BSc in Experimental Pathology (1st Class Honours) and MBBS with Distinction from Guy’s, King’s and St Thomas’ School of Medicine, University of London, UK. He undertook training in internal medicine at Hammersmith Hospital and Guy’s and St Thomas’ Hospitals in London, and obtained his MRCP(UK) in 2005. In that same year, he was awarded a Cancer Research UK (CRUK) Clinical Research Fellowship at The Institute of Cancer Research (the academic partner institution of The Royal Marsden Hospital), London, where he did research in ovarian and breast cancers and obtained his PhD in Oncology. He subsequently completed his specialist training in Medical Oncology at The Royal Marsden Hospital, London. After working in the Drug Development Unit at The Royal Marsden Hospital/ Institute of Cancer Research, he went on to complete another fellowship at the Princess Margaret Cancer Centre, University of Toronto, Canada, in Drug Development and Gynaecologic Oncology before returning back to Singapore.
In addition to his clinical and academic duties, he is currently also the Associate Chairman Medical Board for Research at the National University Hospital, Singapore and Head of the Innovation Transfer Office at National University Health Systems (NUHS). He is also a member of the Novel Agents Committee for Cancer (NACC) at the Experimental Therapeutics Centre in A*STAR Singapore.
Education and Fellowships
- BSc(Hons)(London), MBBS(Distinction)(London), PG Dip(Oncology), MRCP(UK)(Medical Oncology), PhD(London), FRCP(Edin)
- 2005-2008: Cancer Research UK Clinical Research Fellowship, The Institute of Cancer Research, London, UK - PhD
- 2008-2012: The Royal Marsden Hospital Medical Oncology Training Rotation, London, UK - Certificate of Completion of Training (CCT) in Medical Oncology and MRCP(UK)(Medical Oncology)
- 2012-2013: Fellowship in Gynaecologic Oncology and Drug Development, Princess Margaret Cancer Centre, University of Toronto, Canada
Awards and Honours
- 1996 1st Year Distinction in Basic Medical Sciences, Guy’s & St Thomas’ Hospitals Medical School, University of London
- 1998 BSc Prize for Experimental Pathology, Guy’s & St Thomas’ Hospitals Medical School, University of London
- 1999 3rd Year Merit Award, Guy’s King’s & St Thomas’ School of Medicine, University of London
- 2000 4th Year Merit Award, Guy’s King’s & St Thomas’ School of Medicine, University of London
- 2001 5th Year Merit Award, Guy’s King’s & St Thomas’ School of Medicine, University of London
- 2001 MBBS with Distinction, Guy’s King’s & St Thomas’ School of Medicine, University of London
- 2005 Cancer Research UK Clinical Research Fellowship Award
- 2007 Sir Alastair Currie Prize (Best Scientific Poster Presentation, 4th Meeting of the British Division of the IAP and the Pathological Society of Great Britain and Ireland)
- 2008 Young Investigator Award (5th European Congress: Perspectives in Gynaecologic Oncology, Cannes, France)
- 2011 Travelling Fellowship Award for the Helene Harris Memorial Trust 12th International Forum on Ovarian Cancer, Miami, Florida
- 2012 AACR-ECCO-ASCO Fellowship for FLIMS 14 Workshop on Methods in Clinical Cancer Research
- 2013 Singapore National Medical Research Council (NMRC) Transition Award
- 2014 European Society of Medical Oncology Travel Grant Award
- 2016 Singapore National Medical Research Council (NMRC) Clinician Scientist Award
- American Society of Clinical Oncology
- The Royal College of Physicians, London, UK
- European Society of Medical Oncology
- Gynaecologic Cancer
- Drug Development/ Phase I trials
- David SP Tan, Stan Kaye. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? American Society of Clinical Oncology Education Book. 2015:114-21.
- Wong AL, Lim JS, Sinha A, Gopinathan A, Lim R, Tan CS, Soh T, Venkatesh S, Titin C, Sapari NS, Lee SC, Yong WP, Tan DS, Pang B, Wang TT, Zee YK, Soong R, Trnkova Z, Lathia C, Thiery JP, Wilhelm S, Jeffers M, Goh BC. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. J Transl Med. 2015 Feb 12;13:57.
- Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Emma Kipps, David SP Tan, Stan B Kaye. Nature Reviews Cancer 2013 Apr;13(4):273-82.
- David SP Tan, Timothy A Yap, Margaret Hutka, Patricia Roxburgh, Jooern Ang, Susana Banerjee, Ewa Grzybowska, Charlie Gourley, Martin E Gore, Stan B Kaye. Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. European Journal of Cancer 2012 Dec 19.
- Alan Mackay, Britta Weigelt, Anita Grigoriadis, Bas Kreike, Rachael Natrajan, Roger A’Hern, David SP Tan, Mitch Dowsett, Alan Ashworth, Jorge S Reis-Filho. Microarray-based class discovery for molecular classification of breast cancer: analysis of inter-observer agreement. Journal of the National Cancer Institute 2011 Apr 20;103(8):662-73.
- David SP Tan, Marjan Iravani, W Glenn McCluggage, Maryou Lambros, Fernanda Milanezi, Alan Mackay, Charlie Gourley, Felipe C Geyer, Radost Vatcheva, Joanne Millar, Karen Thomas, Rachael Natrajan, Kay Savage, Kerry Fenwick, Alistair RW Williams, Charles Jameson, Mona El-Bahrawy, Martin Gore, Hani Gabra, Stanley B Kaye, Alan Ashworth and Jorge S Reis-Filho. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clinical Cancer Research 2011 Mar 15;17(6):1521-34.
- Richard Baird, David SP Tan, Stan B Kaye. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nature Reviews Clinical Oncology 2010 Oct;7(10):575-82.
- Britta Weigelt, Alan Mackay, Roger A’hern, Rachael Natrajan, David SP Tan, Mitch Dowsett, Alan Ashworth, and Jorge S Reis-Filho. Breast cancer molecular profiling: a retrospective analysis of molecular subtype assignment using single sample predictors. Lancet Oncology 2010 Apr;11(4):339-49.
- David SP Tan, Maryou BK Lambros, Sydonia Rayter, Rachael Natrajan, Radost Vatcheva, Qiong Gao, Caterina Marchiò, Felipe C Geyer, Kay Savage, Suzanne Parry, Kerry Fenwick, Narinder Tamber, Alan Mackay, Tim Dexter, Charles Jameson, W Glenn McCluggage, Alistair Williams, Ashley Graham, Dana Faratian, Mona El-Bahrawy, Adam J Paige, Hani Gabra, Martin E Gore, Marketa Zvelebil, Christopher J Lord, Stanley B Kaye, Alan Ashworth, Jorge S Reis-Filho. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clinical Cancer Research. 2009 Apr 1;15(7):2269-80.
- David SP Tan, Christian Rothermundt, Karen Thomas, Elizabeth Bancroft, Rosalind A Eeles, Susan Shanley, Audrey Ardern-Jones, Andrew Norman, Stanley B Kaye, Martin E Gore. The “BRCAness” Syndrome in Ovarian Cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA 1/2 mutations. Journal of Clinical Oncology. 2008 Dec 1;26(34):5530-6.
- David SP Tan, Caterina Marchió, Robin L Jones, Kay Savage, Ian E Smith, Mitch Dowsett, Jorge S Reis-Filho. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Research and Treatment 2007 Oct 6
- David SP Tan, Roshan Agarwal, Stanley B Kaye. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncology 2006 Nov;7(11):925-34.